Effect of Statins on Serum Levels of TNF-alpha and Interleukin-6 in Patients with Kidney Disease: A Meta-analysis of Randomized Clinical Trials

IF 2.6 4区医学 Q2 PHARMACOLOGY & PHARMACY

Current pharmaceutical design Pub Date : 2024-04-17 DOI:10.2174/0113816128299493240403084905

Bahman Razi, Saeed Aslani, Danyal Imani, Sajad Salehiyeh, Mahdieh Fasihi, Željko Reiner, Amirhossein Sahebkar

{"title":"Effect of Statins on Serum Levels of TNF-alpha and Interleukin-6 in Patients with Kidney Disease: A Meta-analysis of Randomized Clinical Trials","authors":"Bahman Razi, Saeed Aslani, Danyal Imani, Sajad Salehiyeh, Mahdieh Fasihi, Željko Reiner, Amirhossein Sahebkar","doi":"10.2174/0113816128299493240403084905","DOIUrl":null,"url":null,"abstract":"Background and Objectives: Some clinical trials have indicated the beneficial effects of statins in patients with kidney disease, while others have reported no positive effect of statins in these patients. We conducted this meta-analysis to identify the effects of statins on serum levels of interleukin-6 (IL-6) and Tumor Necrosis Factor Alpha (TNF-α) in patients with kidney disease. Designs and Methods: A systematic literature search was performed using PubMed, Scopus, and Web of Science databases to identify all studies published from inception to August, 2022. The major outcome variable was the Weighted Mean Difference (WMD). Eligible studies were stratified based on target population, intervention duration, dosage and type of statins, and solubility of statins. Results: Meta-analysis performed on seven publications (8 studies), including 213 patients with kidney disease and 188 control individuals, indicated that the concentration of IL-6 was marginally decreased in patients with kidney disease following statin therapy disease (WMD = -1.15 pg/mL; 95% CI = -2.33 to 0.04, P = 0.05, I 2 =68.5%)). The findings of subgroup analysis based on the dosage of statins showed that neither highintensity nor moderate/low-intensity statin treatment could significantly influence the serum level of IL-6. Lipophilic statins were more effective than hydrophilic statins, and they marginally decreased the levels of IL6 (WMD = -1.21 pg/mL; 95% CI = -2.43 to 0, P = 0.05, I2 = 55.7%)). Meta-analysis of four publications (five studies) with 157 patients with kidney disease and 132 control subjects showed that statins reduced the serum levels of TNF-α in patients with kidney disease when compared with control individuals (WMD= -2.66 pg/mL; 95% CI = -4.26 to -1.06, P < 0.001, I2 = 63%). Conclusion: Statins only marginally decreased the concentration of IL-6 in patients with kidney disease, but neither high-intensity nor moderate/low-intensity statin treatment could significantly influence the level of IL6. However, statins reduced serum levels of TNF-α in patients with kidney disease.","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":"18 1","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical design","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113816128299493240403084905","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and Objectives: Some clinical trials have indicated the beneficial effects of statins in patients with kidney disease, while others have reported no positive effect of statins in these patients. We conducted this meta-analysis to identify the effects of statins on serum levels of interleukin-6 (IL-6) and Tumor Necrosis Factor Alpha (TNF-α) in patients with kidney disease. Designs and Methods: A systematic literature search was performed using PubMed, Scopus, and Web of Science databases to identify all studies published from inception to August, 2022. The major outcome variable was the Weighted Mean Difference (WMD). Eligible studies were stratified based on target population, intervention duration, dosage and type of statins, and solubility of statins. Results: Meta-analysis performed on seven publications (8 studies), including 213 patients with kidney disease and 188 control individuals, indicated that the concentration of IL-6 was marginally decreased in patients with kidney disease following statin therapy disease (WMD = -1.15 pg/mL; 95% CI = -2.33 to 0.04, P = 0.05, I 2 =68.5%)). The findings of subgroup analysis based on the dosage of statins showed that neither highintensity nor moderate/low-intensity statin treatment could significantly influence the serum level of IL-6. Lipophilic statins were more effective than hydrophilic statins, and they marginally decreased the levels of IL6 (WMD = -1.21 pg/mL; 95% CI = -2.43 to 0, P = 0.05, I2 = 55.7%)). Meta-analysis of four publications (five studies) with 157 patients with kidney disease and 132 control subjects showed that statins reduced the serum levels of TNF-α in patients with kidney disease when compared with control individuals (WMD= -2.66 pg/mL; 95% CI = -4.26 to -1.06, P < 0.001, I2 = 63%). Conclusion: Statins only marginally decreased the concentration of IL-6 in patients with kidney disease, but neither high-intensity nor moderate/low-intensity statin treatment could significantly influence the level of IL6. However, statins reduced serum levels of TNF-α in patients with kidney disease.

查看原文本刊更多论文

他汀类药物对肾病患者血清 TNF-α 和白细胞介素-6 水平的影响：随机临床试验的元分析

背景和目的：一些临床试验表明他汀类药物对肾病患者有益，而另一些临床试验则报告他汀类药物对这些患者没有积极作用。我们进行了这项荟萃分析，以确定他汀类药物对肾病患者血清中白细胞介素-6（IL-6）和肿瘤坏死因子α（TNF-α）水平的影响。设计与方法：使用 PubMed、Scopus 和 Web of Science 数据库进行系统性文献检索，以确定从开始到 2022 年 8 月发表的所有研究。主要结果变量为加权平均差（WMD）。根据目标人群、干预持续时间、他汀类药物的剂量和类型以及他汀类药物的溶解度对符合条件的研究进行了分层。结果对7篇文献（8项研究）（包括213名肾病患者和188名对照者）进行的元分析表明，肾病患者在接受他汀类药物治疗后，IL-6浓度略有下降（WMD = -1.15 pg/mL；95% CI = -2.33 to 0.04，P = 0.05，I 2 =68.5%））。基于他汀类药物剂量的亚组分析结果表明，无论是高强度还是中/低强度的他汀类药物治疗都不能显著影响血清中的IL-6水平。亲脂性他汀类药物比亲水性他汀类药物更有效，它们能轻微降低IL6水平（WMD = -1.21 pg/mL; 95% CI = -2.43 to 0, P = 0.05, I2 = 55.7%））。对4篇文献（5项研究）中的157名肾病患者和132名对照组受试者进行的元分析表明，与对照组相比，他汀类药物可降低肾病患者血清中的TNF-α水平（WMD=-2.66 pg/mL；95% CI = -4.26 to -1.06, P < 0.001, I2 = 63%）。结论他汀类药物只能略微降低肾病患者体内 IL-6 的浓度，但无论是高强度还是中/低强度的他汀类药物治疗都不能显著影响 IL6 的水平。然而，他汀类药物能降低肾病患者血清中 TNF-α 的水平。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current pharmaceutical design 医学-药学

CiteScore

6.30

自引率

0.00%

发文量

302

审稿时长

2 months

期刊介绍： Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field. Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.